Lu AF28996

Asset

D1/D2 receptor dopamine agonist for advanced Parkinson's disease

Stage: Phase 2
Modality: Small molecule
Target: DRD2; 1
Indication: 0
Trials: 1
Developer

Indications

1

Parkinson's disease
Phase 2, prnewswire.com, 6 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Competitors12

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 2 sources